PBAC's latest decision on Febuxostat: Not recommended (2017). Considered for Treatment of chronic gout in patients with a contraindication to, or intolerant of treatment with allopurinol.
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2014
Submissions
3
2014 → 2017
Eligible population
Adults with chronic gout who have a contraindication to, or are intolerant of, allopurinol.
Therapy area
Rheumatology
Line of therapy
Second-line
Evidence base
Not applicable
Comparator
probenecid
Economic model
Not modelled
ICER note
Not modelled — minor submission requesting streamlined access to existing Authority Required listing; no new economic evaluation undertaken.
Risk sharing
Risk-sharing arrangement in place — Risk Sharing Agreement in place to reduce risk of unexpected Commonwealth expenditure if febuxostat used beyond the recommended listing; expenditure cap based on conservative estimate of allopurinol-intolerant patients.
Why PBAC said no
Reasons cited in the latest PSD: paucity of evidence of efficacy and safety in allopurinol insufficient patients, risk of prescribing behaviour outside of current PBS restriction, Authority Required restriction considered appropriate as useful signal regarding appropriate prescribing
Submission history
Mar 2014: Not recommended · Authority Required
Mar 2015: Recommended with restriction · Authority Required